Overview

25-Gauge Vitrectomy With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in China

Status:
Unknown status
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
Proliferative diabetic retinopathy(PDR) is the leading cause of visual loss in diabetic patients. Operation is an efficient method to treat PDR. Anti-vascular endothelial growth factor (anti-VEGF) can be used as an adjuvant therapy which can make operation more easy.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
JUNYAN ZHANG
Collaborator:
The First People's Hospital of Xuzhou
Treatments:
Ranibizumab
Triamcinolone
Triamcinolone Acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide